Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA. Shares in the company gained almost 24% ...
Pink spent New Year’s Eve reflecting on the end of the Year of the Wood Snake and welcoming in the Year of the Fire Horse, defined by courage, optimism, and brave actions. On Instagram, the singer ...
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering ...
Hosted on MSN
Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Access detailed historical stock prices, including daily closing prices, for RXRX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback